New drug SH006 tested in patients with advanced solid tumors
NCT ID NCT07362264
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It is not yet known if the drug can effectively fight cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SH006 injection
- What this could lead to
- If this trial shows the drug is safe and tolerable, it could lead to a recommended dose for larger studies testing whether SH006 can shrink tumors or slow cancer growth.
- What could go wrong
- This is a very early Phase 1 trial with only 50 people, so the main goal is safety, not effectiveness. The drug may not work against the cancer, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- A new test could reveal how radiation affects the liver
- Can a protein calm the immune System's overreaction to cancer treatment?